Insider · CIK 0001388406

Chadwick Jeremy G

Reports to the SEC for 2 companies · WATERTOWN, MA

sec.gov

Transactions

Companies

Filings

CIK

0001388406

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-05-27	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−3,679 sh	$81.50	−$300K	44,618
2026-05-27	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−600 sh	$82.08	−$49.2K	44,018
2026-05-26	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−3,730 sh	$78.36	−$292K	57,472
2026-05-26	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−324 sh	$79.17	−$25.7K	57,148
2026-05-26	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−3,800 sh	$79.39	−$302K	53,348
2026-05-26	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−4,500 sh	$80.02	−$360K	48,848
2026-05-26	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−551 sh	$80.71	−$44.5K	48,297
2026-04-22	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+100 sh	$30.17	+$3,017	61,302
2026-04-22	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+200 sh	$43.50	+$8,700	61,502
2026-04-22	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−300 sh	$90.00	−$27K	61,202
2026-04-22	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−100 sh	—	—	45,434
2026-04-22	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−200 sh	—	—	58,263
2026-04-15	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+1,300 sh	$43.50	+$56.6K	62,502
2026-04-15	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−1,300 sh	$90.00	−$117K	61,202
2026-04-15	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−1,300 sh	—	—	58,463
2026-04-14	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+4,466 sh	$30.17	+$135K	65,668
2026-04-14	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+785 sh	$43.50	+$34.1K	66,453
2026-04-14	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−5,251 sh	$90.00	−$473K	61,202
2026-04-14	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−4,466 sh	—	—	45,534
2026-04-14	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−785 sh	—	—	59,763
2026-04-01	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+14.6K sh	$29.64	+$434K	75,842
2026-04-01	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−13.5K sh	$85.41	−$1.16M	62,302
2026-04-01	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−1,100 sh	$86.05	−$94.7K	61,202
2026-04-01	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−14.6K sh	—	—	68,633
2026-03-31	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+7,600 sh	$29.64	+$225K	68,802
2026-03-31	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−7,600 sh	$85.38	−$649K	61,202
2026-03-31	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−7,600 sh	—	—	83,273
2026-03-25	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+24.7K sh	$29.64	+$733K	85,929
2026-03-25	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−24.7K sh	$80.26	−$1.98M	61,202
2026-03-25	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−24.7K sh	—	—	90,873
2026-03-23	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+84.4K sh	$29.64	+$2.5M	152,452
2026-03-23	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−22.8K sh	$76.73	−$1.75M	129,696
2026-03-23	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−53K sh	$77.21	−$4.09M	76,721
2026-03-23	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−8,214 sh	$78.40	−$644K	68,507
2026-03-23	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−6,105 sh	$79.87	−$488K	62,402
2026-03-23	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−1,200 sh	$80.05	−$96.1K	61,202
2026-03-23	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−84.4K sh	—	—	115,600
2026-03-11	KYMRKymera Therapeutics, Inc.M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	+20K sh	$43.50	+$870K	93,810
2026-03-11	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−1,765 sh	$82.13	−$145K	92,045
2026-03-11	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−12.9K sh	$83.10	−$1.07M	79,163
2026-03-11	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−11.1K sh	$83.72	−$930K	68,052
2026-03-11	KYMRKymera Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Operating Officer	MExercise/Conversion	−20K sh	—	—	60,548
2026-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−394 sh	$84.00	−$33.1K	77,335
2026-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−2,017 sh	$85.04	−$172K	75,318
2026-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−1,150 sh	$85.78	−$98.6K	74,168
2026-03-04	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−358 sh	$86.62	−$31K	73,810
2026-03-02	KYMRKymera Therapeutics, Inc.A Award	Chief Operating Officer	AAward	+12.6K sh	—	—	79,768
2026-03-02	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−549 sh	$87.75	−$48.2K	79,219
2026-03-02	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−383 sh	$88.50	−$33.9K	78,836
2026-03-02	KYMRKymera Therapeutics, Inc.S Sale	Chief Operating Officer	SSale	−1,107 sh	$89.66	−$99.3K	77,729

Recent filings

Accepted (ET)
May 274
Chadwick Jeremy G0001193125-26-242266
SEC(opens sec.gov)
Apr 244
Chadwick Jeremy G0001193125-26-177400
SEC(opens sec.gov)
Apr 164
Chadwick Jeremy G0001193125-26-159538
SEC(opens sec.gov)

Companies

Address

C/O KYMERA THERAPEUTICS, INC. 500 NORTH BEACON STREET, 4TH FLOOR

WATERTOWN, MA, 02472